About Biocept

At Biocept, we are dedicated to one thing: improving outcomes for cancer patients. That’s why we focus on developing innovative diagnostic solutions that give patients and doctors the information they need—all from a simple blood test, known as a liquid biopsy.

Our scientific experts have spent years working to change the way physicians look at blood in cancer patients. We have developed a unique, patented methodology to isolate cancer material that is shed into the bloodstream, such as circulating tumor cells, (CTCs) and cell-free circulating tumor DNA (ctDNA). Using our testing service to analyze and interrogate CTCs and ctDNA for certain biomarkers, physicians can be better informed about the actionable molecular information associated with a patient’s cancer. Because we use a simple blood sample, this molecular information can be obtained non-invasively and more rapidly than a tissue biopsy. Additionally, our liquid biopsy tests offer a solution when a tissue biopsy is insufficient or not possible. Using our proprietary liquid biopsy testing service, physicians can obtain information they need to develop a personalized cancer treatment plan for their patients—all from a simple blood test.

Biocept’s services are available to medical and surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical and clinical researchers. Our liquid biopsies have been used by doctors in thousands of patient cases. We partner with industry leaders and major cancer centers, continually advancing the field of cancer diagnostics.

Success Stories

Doctors are already using Biocept to establish biomarker status for thousands of patients.

Learn More